Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02142530
Recruitment Status : Completed
First Posted : May 20, 2014
Last Update Posted : January 25, 2018
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Jeremy Abramson, MD, Massachusetts General Hospital

Brief Summary:
This research study is evaluating a drug called carfilzomib used in combination with another drug called belinostat with participants who have relapsed or refractory non-Hodgkin lymphoma (NHL).

Condition or disease Intervention/treatment Phase
Non-Hodgkin Lymphoma Diffuse Large B-cell Lymphoma Mantle Cell Lymphoma Follicular Lymphoma Peripheral T-cell Lymphoma Drug: Carfilzomib Drug: Belinostat Phase 1

Detailed Description:

The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have NHL, not everyone who participates in this research study will receive the same dose of the study drug. The dose the each participant gets will depend on the number of participants who have been enrolled in the study prior and how the dose was tolerated.

  • Study Drug(s): Both carfilzomib and belinostat will be given through a vein in the participant's arm (IV infusion). Each treatment cycle lasts 28 days (4 weeks).

    • Carfilzomib will be given on Days 1-2, 8-9, and 15-16 of each cycle. The carfilzomib infusion will be given over about 10 minutes during the first cycle. However if the dose is increased over the course of the trial, or if in one of the groups that joins the study at a higher dose level, the infusion will last about 30 minutes. All participants will remain at the clinic under observation for at least 1 hour following each dose of carfilzomib during Cycle 1 and after the Cycle 2 Day 1 dose.
    • Belinostat will be given on Days 1-5 of each cycle. The belinostat infusion will be given over about 30 minutes.
  • Clinical Exams: During all cycles the participant will have a physical exam and will be asked questions about their general health and specific questions about any problems any medications you may be taking.
  • Pharmacokinetic (PK) blood tests: One of the main reasons for this study is to find the highest dose of the study drug combination that can be used safely without experiencing severe side effects to use for future studies. Once this dose is found (the maximum tolerated dose, or MTD), additional blood samples will be drawn from a small set of participants (about 5 participants total) to learn more about the activity of the study drugs in the body over a period of time, including the ways the study drugs are absorbed, distributed, and then released from the body. If participating in this group (the participant will be informed from the Investigator) these pharmacokinetic (PK) samples will be drawn repeatedly over a period of 24 hours on certain days: Blood samples will be drawn at 0, 15, 30, 60, 90 minutes, and 2, 4, 6, 8 and 24 hours after the study drug dosing on Days 1-2, 4-5, and 9 of Cycle 1.
  • Scans (or Imaging tests): Tumor assessment by CT or PET CT scans once every 8 weeks (every other cycle).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase 1 Study
Study Start Date : October 2014
Actual Primary Completion Date : March 2017
Actual Study Completion Date : January 2018

Arm Intervention/treatment
Experimental: Carfilzomib/ Belinostat

Carfilzomib and Belinostat will be administered on a 28-day schedule.

  • Carfilzomib will be given on days 1-2, 8-9, and 15-16 of each cycle, beginning at a dose of 20 mg/m2 (dose level 0).
  • Belinostat will be given on days 1-5 beginning at a dose of 600 mg/m2.
  • Belinostat dosing will precede carfilzomib dosing on days when both drugs are administered. In dose level 1 and beyond, carfilzomib will be given at a dose of 20mg/m2 with cycle 1, and then escalated with cycle 2
  • A maximum of four dose levels are planned with carfilzomib escalated no higher than 20/36 mg/m2 and belinostat escalated no higher than 900 mg/m2.
Drug: Carfilzomib
Other Name: Kyprolis®

Drug: Belinostat
Other Name: Beleodaq

Primary Outcome Measures :
  1. Maximum tolerated doses of carfilzomib and belinostat in combination [ Time Frame: Baseline, 28 days ]

Secondary Outcome Measures :
  1. Number of Participants with Serious Adverse Events [ Time Frame: 28 days ]
  2. Plasma Concentration Time Profiles [ Time Frame: 0, 5, 15, 30, 60, 90 min and 2, 4, 6, 8, and 24 hours ]
    Limited PK assessment to characterize the plasma concentration time profiles at times when the two compounds are given together and alone during the first cycle of therapy in a group of 5 patients treated with the MTD of the combination

  3. Objective response rate [ Time Frame: 8 Weeks ]
    Preliminary assessment of efficacy of carfilzomib and belinostat based on objective response rate For the purposes of this study, participants with measurable disease should be re-evaluated every 8 weeks. Participants with low-grade histologies will be staged and re-staged with CT scans of the chest, abdomen, and pelvis. Participants with high-grade histologies will be staged and re-staged with PET/CT scans.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have histologically confirmed relapsed or refractory non-Hodgkin lymphoma that is not a candidate for standard curative therapy. NHL subtypes include: Diffuse large B-cell lymphoma (DLBCL), Mantle cell lymphoma, Marginal zone lymphoma, Lymphoplasmacytic lymphoma, Peripheral T-cell lymphomas, and Follicular lymphoma of any grade.
  • Patients must have received at least one prior systemic therapy for lymphoma. A washout period of at least 3 weeks is required from the most recent prior therapy.
  • Age ≥18 years
  • ECOG performance status ≤ 2 (Karnofsky ≥ 60%, see Appendix A)
  • Participants must have organ and marrow function as defined below:

    • absolute neutrophil count ≥1,000/mcL
    • platelets ≥75,000/mcL
    • total bilirubin ≤ 2 × institutional upper limit of normal
    • AST(SGOT)/ALT(SGPT) ≤ 3 × institutional upper limit of normal
    • creatinine ≤1.5 × institutional upper limit of normal

      --- OR

    • creatinine clearance ≥45 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
  • Participants may have either measurable or non-measurable disease, but in all cases eligible patients must have disease that can be clinically evaluated for improvement or progression.
  • Patients must have fully recovered from major surgery and from the acute toxic effects of prior chemotherapy and radiotherapy (residual grade 1 toxicity, e.g., grade 1 peripheral neuropathy, and residual alopecia are allowed).
  • The effects of carfilzomib and belinostat on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study drug administration.
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Participants who have had chemotherapy or radiotherapy within 3 weeks (8 weeks for radioimmunotherapy) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier.
  • Participants who are receiving any other investigational agents.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or belinostat
  • Patients with a systemic fungal, bacterial, viral, or other infection not controlled
  • Pregnant or lactating patients.
  • Prior history of another malignancy (except for non-melanoma skin cancer, in situ cervical or breast cancer, or prostate cancer detectable only by PSA) unless disease free for over one year
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Congestive heart failure of any severity (NYHA class I-IV)
  • Any active angina or any unstable angina pectoris or myocardial infarction within one year of study entry.
  • Left ventricular ejection fraction below the lower limit of normal
  • Greater than grade 1 peripheral neuropathy at baseline
  • Congenital long QT syndrome or history of torsades de pointes
  • Baseline QTc interval > 500 msec
  • Concomitant medications required on dosing days that increase risk of torsades de pointes
  • Subjects with known HIV infection
  • Active hepatitis B or C infection
  • Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
  • Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
  • Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02142530

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Beth-Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Massachusetts General Hospital
National Comprehensive Cancer Network
Layout table for investigator information
Principal Investigator: Jeremy Abramson, MD Massachusetts General Hospital
Layout table for additonal information
Responsible Party: Jeremy Abramson, MD, Principal Investigator, Massachusetts General Hospital Identifier: NCT02142530    
Other Study ID Numbers: 14-096
First Posted: May 20, 2014    Key Record Dates
Last Update Posted: January 25, 2018
Last Verified: January 2018
Keywords provided by Jeremy Abramson, MD, Massachusetts General Hospital:
Marginal zone lymphoma
lymphoplasmacytic lymphoma
Waldenstrom's macroglobulinemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Lymphoma, Mantle-Cell
Lymphoma, T-Cell, Peripheral
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, B-Cell
Lymphoma, T-Cell
Antineoplastic Agents
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action